We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Epistem | EHP | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 85.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 85.00 | 85.00 |
| Top Posts |
|---|
Posted at 28/10/2015 15:32 by azzi Unfortunately I have read the briefing note a few times now and believe they have some very deep problems with the flagship technology right now. I understand the care needed to message the city, however in this instance you don`t have to read too much between the lines to recognise that EHP will need more time and more cash to get themselves back on track. In fairness to the interim CEO, he appears to have made some honest remarks which is refreshing to see. |
Posted at 14/8/2015 15:16 by azzi Ghost, I have been an EHP supporter for years but I clearly gauged the prospect incorrectly - my mistake. Through my own findings and conclusions I have decided not to re-invest, I may well be wrong again, however I have made my decision.End. |
Posted at 14/8/2015 09:56 by azzi Yes there are some significant differences - I do not know the pricing strategy employed by EHP. As I mentioned , my concern is whether the EHP technology is really proving itself in the field. I anticipated a raft of positive news flow at this time, maybe it is too soon, however the share price decline and sudden departure of the CEO isn`t positive. |
Posted at 14/8/2015 08:34 by azzi Ghost, I should add that I invested in EHP several years ago. I believed the claims and the story. However, as you will see, even a limited amount of research highlights that EHP are playing in an increasingly crowded market for molecular biology MTB testing. My big, big,worry is that genedrive is not performing as expected. |
Posted at 14/8/2015 08:21 by azzi Ghost - Well to start with Luminex/Cepheid and GenXpert, these received WHO approval for Tb in 2010. Simply search "GeneXpert MTB/RIF" in Wikipedia for starters - I assume all investors conduct such searches as a matter of routine.You will see that it is a direct competitor to EHP - sure there are differences but their technology has been in the market for nearly 5 years already - there is nothing novel about MTB/RIF testing! Once you have researched some of the valuable references cited, take a look at the WHO site and search under TB and you will find many more companies playing in the same field - it should be an eye opener. |
Posted at 12/8/2015 09:19 by azzi I still monitor EHP after selling out at a loss some months ago. I stated that something wasn`t quite right with the company, I think recent events and the share price confirms this. As I have watched the decline in the sp, I have been doing some digging to find out what the prospects of the flagship product, Genedrive, really is. After all there could still be a chance to re-invest for a profit!Unfortunately I am concluding that Genedrive is just another testing platform among an ever growing battery of molecular diagnostic devices. I worry that problems with the technology (as mentioned in Mathew Walls updates over the past 18 months)indicate fundamental weaknesses with both performance and reliability. This would explain the non existing take up in India so far. We were led to believe that Genedrive was a "disruptive" technology that would transform point of care testing - sorry, but I think EHP are being left behind, their competitors in the field are possibly years ahead of them, yet still those competitors struggle to gain traction in India. Possibly we are missing something - we know TB is endemic in parts of India, the existing testing regimes prove this, however, do the government have the resources to fund the best treatments for all those affected? I have it on good authority that they don`t. So what real benefits does a rapid test provide in India? I am applying this rationale to many other models globally and coming up with the same conclusion. I thinks Bigmans atatement, "the Emperors new clothes" sums it up. My recent and current searches on EPH have found nothing positive at all at a time when I would argue positive news flow should be accelerating. I have followed the company for years and will continue to do so. however, no more green from me. Azzi |
Posted at 23/4/2015 09:42 by azzi As I said before, I am genuinely pleased for EHP. However the news appears to have been priced in. I will watch how the story unfolds, the Indian market may not bee that easy to crack, EHP already have competitors providing exactly the same assay for Tb in India. Still todays news is a crucial step forward. |
Posted at 24/3/2015 19:15 by azzi Hi Bigman,You and others might say, "why am I posting and still checking the BB if I have sold out?" My response is simple - because I am a human being who is still curious to find out how EHP perform. I would not have invested in this company if I had not believed in its potential, full stop! Unfortunately all the indicators have told my I was wrong to invest (on two occasions) even though , like you Bigman, I love the sector AND the story. The problem appears to be the messenger - whoever that is in reality? I am concluding that AIM listed companies lack the true transparency and rigour surrounding their claims compared to main market stocks. Hence my decision to walk away from AIM stocks. Naive....yes, after 30 years of investing I can still be hoodwinked! So I will continue to watch over the next few days as, like yourself, if we get positive news, I might re-invest - despite my comment - AIM is not for me! Why? Very simply, because IF Epistem have the technology that can transform point of care diagnostics where so, so many companies have failed to deliver, then it will be a good long term bet! Ny investment will be based on fact rather than hype which is so prevalent with AIM stocks. Failure to deliver on the many promises by stating "exceptional circumstances", "unexpected delays" etc. etc etc. will not be acceptable any longer - and heads should be on the block at all levels! The competition is significant in the markets in which EHP operate, I genuinely hope that the leaders within Epistem are have the required talent, integrity and long term vision to take this company forward. Sorry - a very long message but this company is on the brink of success or failure. Azzi |
Posted at 26/10/2014 19:37 by azzi There must be some problem as EHP should be well on track to deliver on their promise to launch the Genedrive Tb technology by the end of this year?Bigman you are correct, I hold 2 AIM biotechs which I always say are for entertainment. The truth is I also want to make money out of them. I guess I am just fascinated to follow the psychology of AIM companies - this primarily relates to the directors. It appears to me AIM is a mechanism for some brass necked individuals free of any morals and ethics to freely spend the money of their investors whilst keeping price sensitive info very close to their chest. So I say - time to come clean Epistem - you've talked the talk...... Azzi |
Posted at 22/8/2014 20:55 by azzi Thanks for the info folks! I haven't had much time to follow EHP's progress over the past week so just catching up. EHP is one of only two Aim stocks I hold, unfortunately both are behaving as do most AIM stocks - chaotic. We need some very positive progress updates, no bad news, no excuses. High Risk - High Reward (but not always high reward on aim!!)Az. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
